Torquetenovirus Dynamics and Immune Marker Properties in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Longitudinal Study
•Torquetenovirus (TTV) viremia occurred universally and was sustained throughout the first year after hematopoietic stem cell transplantation.•Lymphoid malignancy, antithymocyte globulin, and acute graft-versus-host disease had temporary effects on TTV dynamics.•TTV levels correlated with cytomegalo...
Gespeichert in:
| Veröffentlicht in: | Biology of blood and marrow transplantation 2018-01, Vol.24 (1), p.194-199 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 199 |
|---|---|
| container_issue | 1 |
| container_start_page | 194 |
| container_title | Biology of blood and marrow transplantation |
| container_volume | 24 |
| creator | Wohlfarth, Philipp Leiner, Michael Schoergenhofer, Christian Hopfinger, Georg Goerzer, Irene Puchhammer-Stoeckl, Elisabeth Rabitsch, Werner |
| description | •Torquetenovirus (TTV) viremia occurred universally and was sustained throughout the first year after hematopoietic stem cell transplantation.•Lymphoid malignancy, antithymocyte globulin, and acute graft-versus-host disease had temporary effects on TTV dynamics.•TTV levels correlated with cytomegalovirus and Epstein-Barr virus levels during phases of viremia.
Torquetenovirus (TTV) has been proposed as a marker of immune function in patients receiving immunosuppression after solid organ transplantation. This study aimed to define TTV plasma dynamics and investigate clinical associations in patients following allogeneic hematopoietic stem cell transplantation (HSCT). This was a single-center prospective longitudinal study involving 50 consecutive patients treated with HSCT between March 2015 and April 2016. TTV plasma DNA levels were measured with quantitative PCR at 12 consecutive time points during the first year after HSCT. Forty of the 50 patients (80%) had detectable TTV viremia before HSCT (median level, 5.37 log10 copies/mL; interquartile range [IQR], 3.51-6.44 log10 copies/mL). All patients subsequently developed TTV viremia during the follow-up period. Plasma viral loads evolved dynamically over time, with a peak of 8.32 log10 copies/mL (IQR, 7.33-9.35 log10 copies/mL) occurring at 79 days (IQR, 50-117 days) following HSCT and a stable plateau toward the end of the follow-up period. The type of malignancy, the use of antithymocyte globulin during conditioning, and the occurrence of acute graft-versus-host disease requiring systemic therapy had temporary effects on TTV dynamics. TTV levels showed a significant correlation with absolute lymphocyte counts following engraftment (rs = -.27; P |
| doi_str_mv | 10.1016/j.bbmt.2017.09.020 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1951560374</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1083879117307632</els_id><sourcerecordid>1951560374</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-8e2c32fcac4d3dfd9f3c0910bf49802c51448ebf2e90386a0d700291bd899e983</originalsourceid><addsrcrecordid>eNp9UcGO0zAUjBCIXRZ-gAPykUvCs500MeJSFZZdqYiVKGfLsV8ql8QOtlPUv-FTcdWFI6c3T5oZvTdTFK8pVBTo6t2h6vspVQxoW4GogMGT4po2jJerhq-eZgwdL7tW0KviRYwHAGjrTjwvrpgAzljLr4vfOx9-LpjQ-aMNSyQfT05NVkeinCH307Q4JF9U-IGBPAQ_Y0gWI7GOPKiMXIrk1o-j_2Xdnqwz2KNDq8kdTir52VtMefuWcCIbHEeyC8rFeVQuZbl378n6bBtn1MkekWy929u0GOvUmFWLOb0sng1qjPjqcd4U328_7TZ35fbr5_vNelvqGiCVHTLN2aCVrg03gxED1yAo9EMtOmC6oXXdYT8wzK93KwWmBWCC9qYTAkXHb4q3F985-BxITHKyUeeTlUO_RElFQ5sV8LbOVHah6nx5DDjIOdhJhZOkIM_NyIM8NyPPzUgQMjeTRW8e_Zd-QvNP8reKTPhwIWD-8mgxyKhzwBqNDTkdabz9n_8fVYWjbA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1951560374</pqid></control><display><type>article</type><title>Torquetenovirus Dynamics and Immune Marker Properties in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Longitudinal Study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Wohlfarth, Philipp ; Leiner, Michael ; Schoergenhofer, Christian ; Hopfinger, Georg ; Goerzer, Irene ; Puchhammer-Stoeckl, Elisabeth ; Rabitsch, Werner</creator><creatorcontrib>Wohlfarth, Philipp ; Leiner, Michael ; Schoergenhofer, Christian ; Hopfinger, Georg ; Goerzer, Irene ; Puchhammer-Stoeckl, Elisabeth ; Rabitsch, Werner</creatorcontrib><description>•Torquetenovirus (TTV) viremia occurred universally and was sustained throughout the first year after hematopoietic stem cell transplantation.•Lymphoid malignancy, antithymocyte globulin, and acute graft-versus-host disease had temporary effects on TTV dynamics.•TTV levels correlated with cytomegalovirus and Epstein-Barr virus levels during phases of viremia.
Torquetenovirus (TTV) has been proposed as a marker of immune function in patients receiving immunosuppression after solid organ transplantation. This study aimed to define TTV plasma dynamics and investigate clinical associations in patients following allogeneic hematopoietic stem cell transplantation (HSCT). This was a single-center prospective longitudinal study involving 50 consecutive patients treated with HSCT between March 2015 and April 2016. TTV plasma DNA levels were measured with quantitative PCR at 12 consecutive time points during the first year after HSCT. Forty of the 50 patients (80%) had detectable TTV viremia before HSCT (median level, 5.37 log10 copies/mL; interquartile range [IQR], 3.51-6.44 log10 copies/mL). All patients subsequently developed TTV viremia during the follow-up period. Plasma viral loads evolved dynamically over time, with a peak of 8.32 log10 copies/mL (IQR, 7.33-9.35 log10 copies/mL) occurring at 79 days (IQR, 50-117 days) following HSCT and a stable plateau toward the end of the follow-up period. The type of malignancy, the use of antithymocyte globulin during conditioning, and the occurrence of acute graft-versus-host disease requiring systemic therapy had temporary effects on TTV dynamics. TTV levels showed a significant correlation with absolute lymphocyte counts following engraftment (rs = -.27; P < .01) and with cytomegalovirus (CMV; rs = .39; P < .01) and Epstein-Barr virus (EBV; rs = .45; P = .02) viral loads during phases of viremia. Immune-related clinical events were not predicted by TTV levels. TTV viremia occurred universally and was sustained throughout the first year after HSCT. Several variables and events before and after HSCT were correlated with TTV levels and hint toward immune marker properties of TTV, but their complex interactions might perturb the capability of TTV to predict immune-related complications in this population.</description><identifier>ISSN: 1083-8791</identifier><identifier>EISSN: 1523-6536</identifier><identifier>DOI: 10.1016/j.bbmt.2017.09.020</identifier><identifier>PMID: 29032273</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Biomarkers - analysis ; Biomarkers - blood ; Cytomegalovirus ; DNA Virus Infections - blood ; DNA Virus Infections - immunology ; DNA, Viral - blood ; Female ; Hematopoietic stem cell transplantation ; Hematopoietic Stem Cell Transplantation - adverse effects ; Herpesvirus 4, Human ; HSCT ; Humans ; Longitudinal Studies ; Lymphocyte Count ; Male ; Prospective Studies ; Torque teno virus - physiology ; Torquetenovirus ; Transplantation, Homologous - adverse effects ; TTV ; Viral Load</subject><ispartof>Biology of blood and marrow transplantation, 2018-01, Vol.24 (1), p.194-199</ispartof><rights>2017 The American Society for Blood and Marrow Transplantation</rights><rights>Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-8e2c32fcac4d3dfd9f3c0910bf49802c51448ebf2e90386a0d700291bd899e983</citedby><cites>FETCH-LOGICAL-c400t-8e2c32fcac4d3dfd9f3c0910bf49802c51448ebf2e90386a0d700291bd899e983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1083879117307632$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29032273$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wohlfarth, Philipp</creatorcontrib><creatorcontrib>Leiner, Michael</creatorcontrib><creatorcontrib>Schoergenhofer, Christian</creatorcontrib><creatorcontrib>Hopfinger, Georg</creatorcontrib><creatorcontrib>Goerzer, Irene</creatorcontrib><creatorcontrib>Puchhammer-Stoeckl, Elisabeth</creatorcontrib><creatorcontrib>Rabitsch, Werner</creatorcontrib><title>Torquetenovirus Dynamics and Immune Marker Properties in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Longitudinal Study</title><title>Biology of blood and marrow transplantation</title><addtitle>Biol Blood Marrow Transplant</addtitle><description>•Torquetenovirus (TTV) viremia occurred universally and was sustained throughout the first year after hematopoietic stem cell transplantation.•Lymphoid malignancy, antithymocyte globulin, and acute graft-versus-host disease had temporary effects on TTV dynamics.•TTV levels correlated with cytomegalovirus and Epstein-Barr virus levels during phases of viremia.
Torquetenovirus (TTV) has been proposed as a marker of immune function in patients receiving immunosuppression after solid organ transplantation. This study aimed to define TTV plasma dynamics and investigate clinical associations in patients following allogeneic hematopoietic stem cell transplantation (HSCT). This was a single-center prospective longitudinal study involving 50 consecutive patients treated with HSCT between March 2015 and April 2016. TTV plasma DNA levels were measured with quantitative PCR at 12 consecutive time points during the first year after HSCT. Forty of the 50 patients (80%) had detectable TTV viremia before HSCT (median level, 5.37 log10 copies/mL; interquartile range [IQR], 3.51-6.44 log10 copies/mL). All patients subsequently developed TTV viremia during the follow-up period. Plasma viral loads evolved dynamically over time, with a peak of 8.32 log10 copies/mL (IQR, 7.33-9.35 log10 copies/mL) occurring at 79 days (IQR, 50-117 days) following HSCT and a stable plateau toward the end of the follow-up period. The type of malignancy, the use of antithymocyte globulin during conditioning, and the occurrence of acute graft-versus-host disease requiring systemic therapy had temporary effects on TTV dynamics. TTV levels showed a significant correlation with absolute lymphocyte counts following engraftment (rs = -.27; P < .01) and with cytomegalovirus (CMV; rs = .39; P < .01) and Epstein-Barr virus (EBV; rs = .45; P = .02) viral loads during phases of viremia. Immune-related clinical events were not predicted by TTV levels. TTV viremia occurred universally and was sustained throughout the first year after HSCT. Several variables and events before and after HSCT were correlated with TTV levels and hint toward immune marker properties of TTV, but their complex interactions might perturb the capability of TTV to predict immune-related complications in this population.</description><subject>Adult</subject><subject>Biomarkers - analysis</subject><subject>Biomarkers - blood</subject><subject>Cytomegalovirus</subject><subject>DNA Virus Infections - blood</subject><subject>DNA Virus Infections - immunology</subject><subject>DNA, Viral - blood</subject><subject>Female</subject><subject>Hematopoietic stem cell transplantation</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Herpesvirus 4, Human</subject><subject>HSCT</subject><subject>Humans</subject><subject>Longitudinal Studies</subject><subject>Lymphocyte Count</subject><subject>Male</subject><subject>Prospective Studies</subject><subject>Torque teno virus - physiology</subject><subject>Torquetenovirus</subject><subject>Transplantation, Homologous - adverse effects</subject><subject>TTV</subject><subject>Viral Load</subject><issn>1083-8791</issn><issn>1523-6536</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UcGO0zAUjBCIXRZ-gAPykUvCs500MeJSFZZdqYiVKGfLsV8ql8QOtlPUv-FTcdWFI6c3T5oZvTdTFK8pVBTo6t2h6vspVQxoW4GogMGT4po2jJerhq-eZgwdL7tW0KviRYwHAGjrTjwvrpgAzljLr4vfOx9-LpjQ-aMNSyQfT05NVkeinCH307Q4JF9U-IGBPAQ_Y0gWI7GOPKiMXIrk1o-j_2Xdnqwz2KNDq8kdTir52VtMefuWcCIbHEeyC8rFeVQuZbl378n6bBtn1MkekWy929u0GOvUmFWLOb0sng1qjPjqcd4U328_7TZ35fbr5_vNelvqGiCVHTLN2aCVrg03gxED1yAo9EMtOmC6oXXdYT8wzK93KwWmBWCC9qYTAkXHb4q3F985-BxITHKyUeeTlUO_RElFQ5sV8LbOVHah6nx5DDjIOdhJhZOkIM_NyIM8NyPPzUgQMjeTRW8e_Zd-QvNP8reKTPhwIWD-8mgxyKhzwBqNDTkdabz9n_8fVYWjbA</recordid><startdate>201801</startdate><enddate>201801</enddate><creator>Wohlfarth, Philipp</creator><creator>Leiner, Michael</creator><creator>Schoergenhofer, Christian</creator><creator>Hopfinger, Georg</creator><creator>Goerzer, Irene</creator><creator>Puchhammer-Stoeckl, Elisabeth</creator><creator>Rabitsch, Werner</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201801</creationdate><title>Torquetenovirus Dynamics and Immune Marker Properties in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Longitudinal Study</title><author>Wohlfarth, Philipp ; Leiner, Michael ; Schoergenhofer, Christian ; Hopfinger, Georg ; Goerzer, Irene ; Puchhammer-Stoeckl, Elisabeth ; Rabitsch, Werner</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-8e2c32fcac4d3dfd9f3c0910bf49802c51448ebf2e90386a0d700291bd899e983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Biomarkers - analysis</topic><topic>Biomarkers - blood</topic><topic>Cytomegalovirus</topic><topic>DNA Virus Infections - blood</topic><topic>DNA Virus Infections - immunology</topic><topic>DNA, Viral - blood</topic><topic>Female</topic><topic>Hematopoietic stem cell transplantation</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Herpesvirus 4, Human</topic><topic>HSCT</topic><topic>Humans</topic><topic>Longitudinal Studies</topic><topic>Lymphocyte Count</topic><topic>Male</topic><topic>Prospective Studies</topic><topic>Torque teno virus - physiology</topic><topic>Torquetenovirus</topic><topic>Transplantation, Homologous - adverse effects</topic><topic>TTV</topic><topic>Viral Load</topic><toplevel>online_resources</toplevel><creatorcontrib>Wohlfarth, Philipp</creatorcontrib><creatorcontrib>Leiner, Michael</creatorcontrib><creatorcontrib>Schoergenhofer, Christian</creatorcontrib><creatorcontrib>Hopfinger, Georg</creatorcontrib><creatorcontrib>Goerzer, Irene</creatorcontrib><creatorcontrib>Puchhammer-Stoeckl, Elisabeth</creatorcontrib><creatorcontrib>Rabitsch, Werner</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biology of blood and marrow transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wohlfarth, Philipp</au><au>Leiner, Michael</au><au>Schoergenhofer, Christian</au><au>Hopfinger, Georg</au><au>Goerzer, Irene</au><au>Puchhammer-Stoeckl, Elisabeth</au><au>Rabitsch, Werner</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Torquetenovirus Dynamics and Immune Marker Properties in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Longitudinal Study</atitle><jtitle>Biology of blood and marrow transplantation</jtitle><addtitle>Biol Blood Marrow Transplant</addtitle><date>2018-01</date><risdate>2018</risdate><volume>24</volume><issue>1</issue><spage>194</spage><epage>199</epage><pages>194-199</pages><issn>1083-8791</issn><eissn>1523-6536</eissn><abstract>•Torquetenovirus (TTV) viremia occurred universally and was sustained throughout the first year after hematopoietic stem cell transplantation.•Lymphoid malignancy, antithymocyte globulin, and acute graft-versus-host disease had temporary effects on TTV dynamics.•TTV levels correlated with cytomegalovirus and Epstein-Barr virus levels during phases of viremia.
Torquetenovirus (TTV) has been proposed as a marker of immune function in patients receiving immunosuppression after solid organ transplantation. This study aimed to define TTV plasma dynamics and investigate clinical associations in patients following allogeneic hematopoietic stem cell transplantation (HSCT). This was a single-center prospective longitudinal study involving 50 consecutive patients treated with HSCT between March 2015 and April 2016. TTV plasma DNA levels were measured with quantitative PCR at 12 consecutive time points during the first year after HSCT. Forty of the 50 patients (80%) had detectable TTV viremia before HSCT (median level, 5.37 log10 copies/mL; interquartile range [IQR], 3.51-6.44 log10 copies/mL). All patients subsequently developed TTV viremia during the follow-up period. Plasma viral loads evolved dynamically over time, with a peak of 8.32 log10 copies/mL (IQR, 7.33-9.35 log10 copies/mL) occurring at 79 days (IQR, 50-117 days) following HSCT and a stable plateau toward the end of the follow-up period. The type of malignancy, the use of antithymocyte globulin during conditioning, and the occurrence of acute graft-versus-host disease requiring systemic therapy had temporary effects on TTV dynamics. TTV levels showed a significant correlation with absolute lymphocyte counts following engraftment (rs = -.27; P < .01) and with cytomegalovirus (CMV; rs = .39; P < .01) and Epstein-Barr virus (EBV; rs = .45; P = .02) viral loads during phases of viremia. Immune-related clinical events were not predicted by TTV levels. TTV viremia occurred universally and was sustained throughout the first year after HSCT. Several variables and events before and after HSCT were correlated with TTV levels and hint toward immune marker properties of TTV, but their complex interactions might perturb the capability of TTV to predict immune-related complications in this population.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29032273</pmid><doi>10.1016/j.bbmt.2017.09.020</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-8791 |
| ispartof | Biology of blood and marrow transplantation, 2018-01, Vol.24 (1), p.194-199 |
| issn | 1083-8791 1523-6536 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1951560374 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | Adult Biomarkers - analysis Biomarkers - blood Cytomegalovirus DNA Virus Infections - blood DNA Virus Infections - immunology DNA, Viral - blood Female Hematopoietic stem cell transplantation Hematopoietic Stem Cell Transplantation - adverse effects Herpesvirus 4, Human HSCT Humans Longitudinal Studies Lymphocyte Count Male Prospective Studies Torque teno virus - physiology Torquetenovirus Transplantation, Homologous - adverse effects TTV Viral Load |
| title | Torquetenovirus Dynamics and Immune Marker Properties in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Longitudinal Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T15%3A59%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Torquetenovirus%20Dynamics%20and%20Immune%20Marker%20Properties%20in%20Patients%20Following%20Allogeneic%20Hematopoietic%20Stem%20Cell%20Transplantation:%20A%20Prospective%20Longitudinal%20Study&rft.jtitle=Biology%20of%20blood%20and%20marrow%20transplantation&rft.au=Wohlfarth,%20Philipp&rft.date=2018-01&rft.volume=24&rft.issue=1&rft.spage=194&rft.epage=199&rft.pages=194-199&rft.issn=1083-8791&rft.eissn=1523-6536&rft_id=info:doi/10.1016/j.bbmt.2017.09.020&rft_dat=%3Cproquest_cross%3E1951560374%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1951560374&rft_id=info:pmid/29032273&rft_els_id=S1083879117307632&rfr_iscdi=true |